In the past 40 years, therapeutic antibody discovery and development have advanced
considerably, with machine learning (ML) offering a promising way to speed up the process …

The adaptive immune system holds invaluable information on past and present immune
responses in the form of B and T cell receptor sequences, but we are limited in our ability to …

The evolving development landscape of biotherapeutics and their growing complexity from
simple antibodies into bi-and multi-specific molecules necessitates sophisticated discovery …

Background Antibodies are composed of light and heavy chains, both of which have
constant and variable regions. The diversity, specific binding ability and therapeutic potential …

A framework for the rational selection of a minimal suite of nondegenerate developability
assays (DAs) that maximize insight into candidate developability or storage stability is …

Antibodies represent the largest class of biotherapeutics thanks to their high target
specificity, binding affinity and versatility. Recent breakthroughs in Artificial Intelligence (AI) …

Antibodies are versatile therapeutic molecules that utilize combinatorial sequence diversity
to cover a vast fitness landscape. However, designing optimal antibody sequences remains …

The successful progression of therapeutic antibodies and other biologics from the laboratory
to the clinic depends on their possession of “drug-like” biophysical properties. The …